The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults

J. Michael Kilby, Jacob P. Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, Jeffrey C. Goodgame, Joel E. Gallant, Paul Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, Emily L. Nelson, Prakash R. Sista, Alex Dusek

Research output: Contribution to journalArticlepeer-review

184 Scopus citations

Abstract

Enfuvirtide (T-20) is a novel antiretroviral agent that blocks HIV-1 cell fusion. A 28-day randomized dose-comparison study was conducted to determine the safety, pharmacokinetics, and antiviral activity of enfuvirtide in 78 HIV-infected adults, most with extensive treatment experience. Patients received enfuvirtide, added to a failing regimen, either by continuous subcutaneous infusion (CSI: 12.5, 25, 50 or 100 mg/day) or by subcutaneous (SC) injection (50 or 100 mg twice daily). Dose-related decreases in viral load were observed, with a maximum mean reduction from baseline of 1.6 log10 copies/ml (p < 0.001) seen in the 100 mg bid SC group. Most responses diminished by 28 days. Plasma pharmacokinetics and antiviral responses were more consistent for SC injection than for CSI because of technical difficulties experienced with CSI. Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment.

Original languageEnglish (US)
Pages (from-to)685-693
Number of pages9
JournalAIDS research and human retroviruses
Volume18
Issue number10
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults'. Together they form a unique fingerprint.

Cite this